Todd Foley Sells 16,562 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) Stock

Repare Therapeutics Inc. (NASDAQ:RPTX) Director Todd Foley sold 16,562 shares of the company’s stock in a transaction on Monday, June 21st. The shares were sold at an average price of $34.50, for a total transaction of $571,389.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Todd Foley also recently made the following trade(s):

  • On Wednesday, June 23rd, Todd Foley sold 622 shares of Repare Therapeutics stock. The shares were sold at an average price of $32.98, for a total transaction of $20,513.56.
  • On Thursday, June 17th, Todd Foley sold 14,328 shares of Repare Therapeutics stock. The shares were sold at an average price of $33.80, for a total transaction of $484,286.40.
  • On Wednesday, June 9th, Todd Foley sold 15,523 shares of Repare Therapeutics stock. The shares were sold at an average price of $34.68, for a total transaction of $538,337.64.
  • On Monday, June 7th, Todd Foley sold 10,186 shares of Repare Therapeutics stock. The shares were sold at an average price of $32.68, for a total transaction of $332,878.48.
  • On Thursday, June 3rd, Todd Foley sold 9,824 shares of Repare Therapeutics stock. The shares were sold at an average price of $31.92, for a total transaction of $313,582.08.
  • On Wednesday, May 26th, Todd Foley sold 10,590 shares of Repare Therapeutics stock. The shares were sold at an average price of $32.76, for a total transaction of $346,928.40.
  • On Monday, May 24th, Todd Foley sold 9,782 shares of Repare Therapeutics stock. The shares were sold at an average price of $34.12, for a total transaction of $333,761.84.
  • On Thursday, May 20th, Todd Foley sold 4,387 shares of Repare Therapeutics stock. The stock was sold at an average price of $34.69, for a total transaction of $152,185.03.
  • On Tuesday, May 18th, Todd Foley sold 10,312 shares of Repare Therapeutics stock. The stock was sold at an average price of $34.16, for a total transaction of $352,257.92.

Shares of Repare Therapeutics stock opened at $33.40 on Friday. The stock has a market cap of $1.24 billion and a price-to-earnings ratio of -8.77. Repare Therapeutics Inc. has a twelve month low of $21.45 and a twelve month high of $46.44. The company has a 50-day moving average of $32.91.

Repare Therapeutics (NASDAQ:RPTX) last released its quarterly earnings data on Thursday, May 13th. The company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.51) by ($0.07). The business had revenue of $0.17 million for the quarter. Equities research analysts expect that Repare Therapeutics Inc. will post -2.44 EPS for the current fiscal year.

RPTX has been the topic of several recent analyst reports. Morgan Stanley increased their target price on shares of Repare Therapeutics from $41.00 to $45.00 and gave the stock an “overweight” rating in a research note on Monday, April 19th. Berenberg Bank initiated coverage on shares of Repare Therapeutics in a research note on Monday, March 1st. They set a “buy” rating and a $51.00 target price on the stock. Finally, Zacks Investment Research lowered shares of Repare Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, June 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Repare Therapeutics has an average rating of “Buy” and an average target price of $40.20.

A number of hedge funds have recently added to or reduced their stakes in the business. BVF Inc. IL raised its holdings in Repare Therapeutics by 25.2% in the 1st quarter. BVF Inc. IL now owns 3,722,398 shares of the company’s stock valued at $114,240,000 after acquiring an additional 750,207 shares during the last quarter. Redmile Group LLC raised its holdings in Repare Therapeutics by 0.7% in the 1st quarter. Redmile Group LLC now owns 2,665,496 shares of the company’s stock valued at $81,804,000 after acquiring an additional 17,800 shares during the last quarter. ARK Investment Management LLC raised its holdings in Repare Therapeutics by 113.8% in the 1st quarter. ARK Investment Management LLC now owns 1,358,589 shares of the company’s stock valued at $41,695,000 after acquiring an additional 723,196 shares during the last quarter. Logos Global Management LP raised its holdings in Repare Therapeutics by 33.0% in the 1st quarter. Logos Global Management LP now owns 900,000 shares of the company’s stock valued at $27,621,000 after acquiring an additional 223,106 shares during the last quarter. Finally, Cormorant Asset Management LP raised its holdings in Repare Therapeutics by 54.1% in the 1st quarter. Cormorant Asset Management LP now owns 462,205 shares of the company’s stock valued at $14,185,000 after acquiring an additional 162,205 shares during the last quarter. Institutional investors own 70.24% of the company’s stock.

About Repare Therapeutics

Repare Therapeutics Inc, a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair.

Further Reading: Different Types of Derivatives

Insider Buying and Selling by Quarter for Repare Therapeutics (NASDAQ:RPTX)

Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.